CellaVision ABCVLLY +12.06%69 ROC (Joel Greenblatt) % is 47.28% as of Mar. 2026, which is 45% below its 10-year median of 86.06. GuruFocus rates CVLLY with a GF Score™ of 69/100 and a GF Value™ of $12.48 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 841 Medical Devices & Instruments companies, CellaVision AB ranks better than 94.17% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. CellaVision AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 47.28%.
The historical rank and industry rank for CellaVision AB's ROC (Joel Greenblatt) % or its related term are showing as below:
CVLLY'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 61.16 Med: 86.06 Max: 327.92
Current: 71.82
During the past 13 years, CellaVision AB's highest ROC (Joel Greenblatt) % was 327.92%. The lowest was 61.16%. And the median was 86.06%.
CVLLY's ROC (Joel Greenblatt) % is ranked better than 94.17% of 841
companies
in the Medical Devices & Instruments industry
Industry Median: 4.13
vs CVLLY: 71.82
CellaVision AB's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -4.00% per year.
CellaVision AB (OTCPK:CVLLY) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
CellaVision AB ROC (Joel Greenblatt) % Related Terms
CellaVision AB ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for CellaVision AB's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CVLLY vs ABT, SYK, MDT: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, CellaVision AB's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellaVision AB ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where CellaVision AB's ROC (Joel Greenblatt) % falls into.
CellaVision AB ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 47.28% mean?
CellaVision AB (CVLLY) has a ROC (Joel Greenblatt) % of 47.28% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on CellaVision AB and its competitors. This is 45% below median its historical median of 86.06. Over the past decade, CellaVision AB's ROC (Joel Greenblatt) % has ranged from 61.16 to 327.92. According to the industry distribution chart, CellaVision AB ranks #49 out of 841 companies in the Medical Devices & Instruments industry, placing it in the top 5.8%.
Is CellaVision AB's ROC (Joel Greenblatt) % too high?
CellaVision AB's current ROC (Joel Greenblatt) % of 47.28% is 45% below median its 10-year median of 86.06. Over the past 10 years, this metric has ranged from a low of 61.16 to a high of 327.92. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.13. CellaVision AB's value of 47.28% is 1044.8% above this industry median. Based on the distribution chart, CellaVision AB ranks #49 out of 841 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, CellaVision AB has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's ROC (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #49 out of 841 companies for ROC (Joel Greenblatt) %. This places CellaVision AB in the top 6% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 4.13. CellaVision AB's value of 47.28% is 1044.8% above this benchmark. Historically, CellaVision AB's own ROC (Joel Greenblatt) % has ranged from 61.16 to 327.92 over the past decade. While the company's 10-year median is 86.06 vs. the industry median of 4.13, CellaVision AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.13, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellaVision AB's current ROC (Joel Greenblatt) % of 47.28% is 1044.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on CellaVision AB and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellaVision AB's current ROC (Joel Greenblatt) % is 47.28%, which is 45% below median its own 10-year median of 86.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
Based on GuruFocus' analysis, CellaVision AB (CVLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.48, compared to a current price of $7.06 — trading 43.4% below its estimated fair value. The current ROC (Joel Greenblatt) % is 47.28%, which is 45% below median its 10-year median of 86.06 and 1044.8% above the Medical Devices & Instruments industry median of 4.13. CellaVision AB's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For CellaVision AB (CVLLY), the current ROC (Joel Greenblatt) % is 47.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellaVision AB (CVLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued.
The current stock price of $7.06 is trading 43.4% below its estimated GF Value™ of $12.48.
GuruFocus considers CellaVision AB to be Significantly Undervalued.
Key valuation signals for CVLLY:
ROC (Joel Greenblatt) %: 47.28% (45% below median its 10-year median of 86.06)
GF Value™: $12.48 vs. price of $7.06 (43.4% below fair value)
Industry Position: 1044.8% above the Medical Devices & Instruments median (#49 of 841)
No single metric tells the full story. See the CVLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
69GF Score
Get the complete analysis for CVLLY
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVLLY has been successfully added to your 
